Tesamorelin & Mod GRF & Ipamorelin (12mg)

Description

Tesamorelin & Mod GRF & Ipamorelin Peptide Blend

Tesamorelin & Mod GRF & Ipamorelin are all synthetic peptides which, albeit via different proposed mechanisms, have exhibited potential to stimulate growth hormone (GH) synthesis and secretion. 

Tesamorelin, a synthetic analogue of the growth hormone-releasing hormone (GHRH), appears to act by specifically stimulating the production and release of endogenous growth hormone (GH). Research suggests it appears to exhibit selective activation of the pituitary gland’s GH-releasing hormone receptors, potentially making it effective in exerting its effects.

Mod GRF is a synthetic peptide that appears to exhibit prolonged half-life as it is likely to resist enzymatic degradation. Research indicates that the peptide appears to act as a potent stimulator of GH secretion – which has shown promise in promoting protein synthesis, muscle growth, and enhanced metabolic processes.

Ipamorelin, a synthetic pentapeptide, appears to act as a selective agonist for the ghrelin receptor and may stimulate the release of GH. It appears to display high specificity and minimal action on other hormonal systems, making it a target for research in GH stimulation.

Chemical Makeup ^{(1) (2) (3)}

Molecular Formula:

• Tesamorelin: C₂₂₁H₃₆₆N₇₂O₆₇S
• Modified GRF: C₁₅₂H₂₅₂N₄₄O₄₂
• Ipamorelin: C₃₈H₄₉N₉O₅

Molecular Weight:

• Tesamorelin: 5136 g/mol
• Modified GRF: 3367.9 g/mol
• Ipamorelin: 711.9 g/mol

Sequence

• Tesamorelin: Unk-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
• Modified GRF: L-tyrosyl-D-alanyl-L-alpha-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-glutaminyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-alpha-aspartyl-L-isoleucyl-L-leucyl-L-seryl-L-argininamide
• Ipamorelin: alpha-methyl-alanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide

Other Known Titles

• Modified GRF: CJC 1295 with DAC
• Ipamorelin: Ipamorelin Acetate

Tesamorelin, Mod GRF & Ipamorelin Research and Clinical Studies

Tesamorelin & Mod GRF & Ipamorelin Blend and the Pituitary Gland

The Tesamorelin & Mod GRF & Ipamorelin peptide blend appear to exhibit significant interactions with the pituitary gland, seemingly exerting potential impact through specific receptor binding and subsequent modulation of growth hormone (GH) release. 

Tesamorelin appears to bind primarily to the GHRH receptors located on the surface of somatotrophs in the anterior pituitary gland. Upon binding, Tesamorelin appears to activate adenylate cyclase and subsequent cyclic adenosine monophosphate (cAMP) production, potentially triggering the release of growth hormone (GH).⁽⁴⁾ Mod GRF appears to interact with GHRH receptors and may act as a potent GH secretagogue. By binding to the GHRH receptors, Mod GRF may enhance GH release and may stimulate protein synthesis, promote muscle growth, and may also enhance metabolic processes, as suggested by scientific research findings. 

Mod GRF peptide has four amino acid substitutions in its structure, which appears to enhance its GH-related activity as well as its potential resistance towards the proteolytic enzymes. These modifications are also believed to assist “at least 90% of the peptide” to bind covalently to blood albumin, with trace amounts potentially binding to fibrinogen and immunoglobulin G (IgG).⁽⁵⁾

As per the researchers, “No other chemical species have been found bound to DAC-GRF after administration This binding extends the half-life of the active pharmacophore, resulting in a markedly prolonged duration of action in several animal species.”⁽⁵⁾

Ipamorelin, on the other hand, appears to act as a selective agonist for the ghrelin receptor, which is also present on somatotrophs within the pituitary gland. Its binding to ghrelin receptors is believed to induce GH release with high specificity and minimal impact on other hormonal systems. Research-based outcomes have indicated that Ipamorelin influence in certain test models may lead to increased GH secretion, without significantly affecting cortisol, prolactin, or insulin levels.⁽⁶⁾

Tesamorelin & Mod GRF & Ipamorelin Blend and the GI Tract

Amongst the three growth hormone releasing peptides, Tesamorelin appears to enhance gastric emptying and improve gastrointestinal motility in animal testing. Researchers also propose that Mod GRF, though minimally, may improve gut barrier function and reduce intestinal inflammation in animal models of colitis.

Ipamorelin is believed to primarily interact with the ghrelin receptor within the GI tract. Upon binding to the ghrelin receptors, Ipamorelin may elicit variety of responses including promoting gut motility and improving intestinal absorption. Moreover, Ipamorelin has shown promise in attenuating inflammation and promoting tissue repair in various models of GI injury. As per researchers, Ipamorelin may “increase total body fat percentages” , identifying the peptide as a “potent and selective stimulator of GH that can significantly influence the GI system, body composition, and adiposity.”⁽⁶⁾

Synergistic Action of Tesamorelin & Mod GRF & Ipamorelin Blend 

The rationale for combining these peptides lies in their supposed distinct mechanisms of action and potential to enhance growth hormone (GH) secretion synergistically. 

In an experimental study⁽⁷⁾, it was indicated that combination of Tesamorelin and Mod GRF led to a synergistic increase in GH secretion compared to either peptide alone. This synergistic effect may be attributed to the complementary mechanisms of action and receptor interactions of these peptides. In clinical trials observing test subjects with HIV-associated lipodystrophy, a combination of Tesamorelin and Ipamorelin appeared to lead to greater reductions in visceral adipose tissue compared to Tesamorelin alone.⁽⁷⁾ As per researchers, this blend appears to “significantly reduce visceral adipose tissue among HIV-infected [subjects] with central fat accumulation. However, this effect is transient and reversed upon cessation of therapy.”⁽⁷⁾

Tesamorelin appears to play a significant role in improving the overall physiological framework of the organism. Studies suggest it has exhibited particularly effective impact on test subjects reaching peak maturity, and as GH production is considered to decline naturally with age, Tesamorelin researchers suggest the peptide may aid in its enhancement. Amongst the three growth hormone-releasing peptides, 

The combined introduction of these three peptides appears to result in a synergistic effect on GH secretion and insulin-like growth factor 1 (IGF-1) levels, potentially leading to increased GH secretion, enhanced muscle growth, improved bone density, cognitive enhancement, cellular repair and regeneration, fat loss, and more. 

Tesamorelin & Mod GRF & Ipamorelin blend is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.

References:

1. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9831659, Ipamorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin. 
2. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 56841945. https://pubchem.ncbi.nlm.nih.gov/compound/56841945. 
3. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 16137828, Tesamorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin. 
4. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tesamorelin. [Updated 2018 Oct 20]. https://www.ncbi.nlm.nih.gov/books/NBK548730/ 
5. Sam L. Teichman and others, Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults, The Journal of Clinical Endocrinology & Metabolism, Volume 91, Issue 3, 1 March 2006, Pages 799–805, https://doi.org/10.1210/jc.2005-1536 ; https://academic.oup.com/jcem/article/91/3/799/2843281 
6. Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108996/ 
7. Bedimo R. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. HIV AIDS (Auckl). 2011;3:69-79. doi: 10.2147/HIV.S14561. Epub 2011 Jul 10. PMID: 22096409; PMCID: PMC3218714. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218714/ 

Dr. Marinov

Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.